
    
      This is a multicenter, open-label, Phase I dose escalation study of
      Tolerability„ÄÅPharmacokinetics and Preliminary antitumor activity of FCN-338 in ascending
      cohorts to determine the MTD or recommended dose in patients with relapsed or refractory
      CLL/SLL patients. This is to be followed by a cohort expansion phase at the MTD or
      recommended oral dose.
    
  